Spyre Therapeutics (NASDAQ:SYRE) saw its stock jump 25% on Monday following the release of 12-week results from Part A of its Phase 2 SKYLINE trial. The company reported that SPY001 achieved the trial's primary endpoint in patients with moderate-to-severely active ulcerative colitis.
According to the data, SPY001 produced a statistically significant 9.2-point drop in the Robarts Histopathology Index score at the 12-week mark. Secondary outcomes reported alongside the primary result included a 40% clinical remission rate and a 51% rate of endoscopic improvement. The Modified Mayo Score fell by 3.7 points from baseline across the treated cohort.
The Part A population comprised 43 enrolled patients. Spyre described the safety profile of SPY001 as consistent with other agents targeting the α4β7 pathway. During the induction period, six subjects experienced treatment-emergent adverse events. One serious adverse event was reported but was assessed as not related to the drug. The most frequently observed adverse event was back pain, which occurred in two patients.
Recruitment for Part A is complete, and the company has commenced enrollment for Part B of SKYLINE. The upcoming phase includes three monotherapy cohorts and three combination cohorts, and will test SPY001 in combination with the company’s investigational antibodies SPY002 and SPY003.
Spyre provided timing expectations for additional readouts. Proof-of-concept induction data for the remaining Part A cohorts are expected in mid-2026 for SPY002 and in the third quarter of 2026 for SPY003. The company also said Part B induction data for all cohorts remains on track for 2027.
Spyre is positioning SPY001 as a potential best-in-class anti-α4β7 antibody, noting an extended half-life in its development strategy aimed at improving upon current inflammatory bowel disease treatments. The reported results from Part A provide initial efficacy and safety signals the company will carry into later-phase evaluation.
Context and market implications
While the data set is limited to the Part A cohort of 43 patients, the magnitude of the histologic improvement and the secondary endpoint outcomes prompted a sizable market reaction. The news is relevant to investors tracking biotechnology and pharmaceutical companies active in inflammatory bowel disease therapeutics, as well as broader healthcare equity indexes where clinical readouts can alter sentiment and valuation dynamics.
What the data do and do not show
The reported findings demonstrate statistical significance on the predefined primary histology measure and indicate clinically meaningful changes in symptomatic and endoscopic assessments within the measured cohort. The safety observations were described as aligning with the known profile for the α4β7 class, though a small number of treatment-emergent events and a single serious event were recorded during induction.